Tucotuzumab celmoleukin is an anti-cancer drug.

It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).

[1][2][3] This drug was developed by EMD Pharmaceuticals.

This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.